Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?  by Del Campo Milan, Marta et al.
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 75–80Cerebrospinal Fluid Biomarkers
Can agrin cerebrospinal fluid concentration be used as an early biomarker
for Alzheimer’s disease?Marta Del Campo Milana,b,*, Leah Zuroffa,b, Connie R. Jimenezc, Philip Scheltensb,
Charlotte E. Teunissena
aNeurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands
bAlzheimer Center, VU University Medical Center, Amsterdam, The Netherlands





creativecommons.org/earliest possible biomarkers. Agrin is increased in the early stages of AD and is involved in amy-
loid-b (Ab) fibrillation and synaptogenesis. We investigated the potential of agrin as an early AD ce-
rebrospinal fluid (CSF) biomarker. We analyzed the agrin CSF concentration in nondemented controls
(n 5 20) and those with mild (n 5 20) and severe (n 5 20) AD. The levels of agrin CSF were not
significantly divergent among the different patient groups and did not correlate with the concentration
of Ab42, total tau, phosphorylated tau, or the Mini Mental State Examination scores. However, agrin
strongly correlated with age in thosewith dementia. The results indicate that agrin cannot be used as an
early AD CSF biomarker using the current immunoassay. However, our population was relatively
young; thus, the correlation between agrin and age suggests that stronger differences in agrin concen-
trations might be found in older groups with more heterogeneous AD pathologic features.
 2015 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Agrin; CSF; Biomarker; Diagnosis; Aging1. Introduction
Alzheimer’s disease (AD) is the most common form of
dementia with an unknown etiology. It is pathologically
characterized by the accumulation of amyloid b (Ab) in se-
nile plaques and phosphorylated tau (p-Tau) in neurofibril-
lary tangles (NFTs). In addition, a remarkable loss of
neurons and synapses is also observed in AD [1,2]. It is
widely accepted that interventions to slow down or halt the
disease should be administered at the earliest possible
stage, before neuronal damage has occurred. Hence, a
strong need exists for the discovery of novel biomarkers
that can better detect this critical phase.uthor. Tel.: 131 (20) 444-3868; Fax: 131 (20) 444-
.delcampomilan@vumc.nl
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blished by Elsevier Inc. on behalf of the Alzheimer’s Associ
licenses/by-nc-nd/4.0/).The current core cerebrospinal fluid (CSF) biomarkers for
AD diagnosis reflect the classic hallmarks of AD pathology:
a decrease in CSF Ab42 levels reflects senile plaque pathol-
ogy and increased total tau (t-Tau) and p-Tau levels reflect
axonal degeneration and NFT formation [3,4]. Their
sensitivity and specificity for AD is high, and they can
reasonably predict the transition of mild cognitive
impairment (MCI) to AD [5]. Nevertheless, AD CSF
biomarker patterns are often present in cognitively normal
subjects and can be influenced by the patient’s age, resulting
in a loss of sensitivity with older age [6,7]. Thus, the quest
for the earliest and most sensitive marker is ongoing.
Interest in biomarkers reflecting synaptic dysfunction has
been increasing because synaptic damage occurs at very
early pathologic stages, preceding neuronal loss, and
strongly correlating with cognitive symptoms [8,9]. In a
previous hypothesis-free proteomics study, several potentialation. This is an open access article under the CC BY-NC-ND license (http://
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including one of the major heparin sulfate proteoglycans,
named agrin (Fig. 1A).
Agrin is expressed in neurons and glia cells [10], and its sup-
pression in mature rat hippocampal cultures severely reduced
the number of synapses formed, indicating a role for agrin in
synaptogenesis [11,12]. In addition, agrin is an important
component of the basal lamina, where it can regulate the
expression of other proteins and influence the permeability of
the blood-brain barrier [13,14]. Several studies have already
implicated agrin in the AD etiology [10,15], because it is the
predominant heparin sulfate proteoglycan associated with
fibrillar and nonfibrillar senile plaques, cerebral amyloid
angiopathy, and neurofibrillary tangles in postmortem AD
tissue [16–18]. Agrin is an amyloid-associated protein able to
enhance Ab fibril formation and to halt Ab degradation [19],
suggesting that agrin might not only be a structural component
of senile plaques but may also contribute to Ab fibrillation.
Importantly, increased soluble agrin levels were found in the
postmortem hippocampus and prefrontal cortex of patients
with AD compared with that in controls [14], with significant
hippocampal changes observed in the very early stages of
AD (Braak III-IV for NFTs) [20,21].
Given the early changes found in human AD tissue and
our recent proteomics data, we hypothesized that agrin is a
potential early synaptic biomarker for AD. Thus, we
analyzed the levels of agrin in the CSF from patients with
AD and controls using a specific enzyme-linked immunosor-
bent assay (ELISA).2. Methods
2.1. Human CSF samples
CSF material (n 5 60) was obtained from the Alzheimer
Center Memory Cohort, NeuroUnit Biomarkers for Inflam-
mation and Neurodegeneration VUMedical Center Biobank
(Amsterdam, The Netherlands). For the initial pilot proteo-
mic study, we selected age-matched patients with AD
(n 5 5; Mini Mental State Examination [MMSE] score
20.8 6 5.6), subjects without dementia with subjective
memory complaints (n5 4; MMSE score 29.56 1), and pa-
tients with MCI who, after 2 years of follow-up, had devel-
oped AD (n 5 5; MMSE score 25 6 2.5) or had remained
stable (n 5 4; MMSE score 28.4 6 2). For the analysis of
agrin in a larger cohort using a specific immunoassay, the pa-
tients without dementia but with subjective memory com-
plaints (n 5 20; MMSE score 27 6 1.78), mild AD
(n 5 20; MMSE score 21.1 6 1.0), and severe AD
(n5 20; MMSE score 15.3 6 1.9) were selected. The diag-
noses were defined in a multidisciplinary meeting, as
described previously [22]. The diagnostic accuracy of
specialized centers such as the Alzheimer Center Amster-
dam has been previously reported [23,24]. Patients were
matched for age and sex. Collection, storage, and analysis
of the CSF biomarkers (Ab1-42, t-Tau, and p-Tau) wereperformed as previously described [5]. The CSF samples
were stored in agreement with the JPND-BIOMARKAPD
guidelines [16]. Patient age, sex, biomarker levels, and
MMSE scores of all cases are listed in Table 1. The ethical
review board of the VU Medical Center approved the study,
and all subjects gave written informed consent.
2.2. Mass spectrometry analysis of CSF
CSF samples were analyzed by label-free gel electropho-
resis liquid chromatography-tandem mass spectrometry-
based proteomics and normalized spectral counting, as
previously described [25]. The data obtained were processed
and analyzed, as described previously [26]. The global pro-
tein profiling results of the CSF proteomics screen will be
reported subsequently (Chiasserini et al, manuscript submit-
ted). Agrin was one of the identified proteins.
2.3. Agrin CSF analyses
The concentration of agrin was determined using the sand-
wich human agrin ELISA kit (Wuxi Donglin Sci & Tech
Development Co., Ltd., Jiangsu, China), in accordance with
the manufacturer’s instructions. Performance of the assay
was evaluated using CSF pools as internal controls. The coef-
ficient of variation (CV) was calculated for each sample in
duplicate as the standard deviation divided by the mean.
The mean CVof all the samples was calculated to establish
the intra-assay CV, which was 8.6%. Samples with an intra-
assay CV greater than 15% were excluded from additional
analysis (n 5 11). Interassay CVs were calculated using
two internal quality control CSF samples in two plates from
one batch, which was 11.4%. For the analysis of clinical sam-
ples, different lots of the agrin ELISAkitwere used inwhich a
larger interlot variation was found for two internal controls
(16.5%). Thus, the agrin concentration for the samples was
corrected for the internal controls used in that assay.
2.4. Statistical analysis
Statistical analyses were performed using SPSS, version
20 (Chicago, IL, USA). Because the data were non-
normally distributed, the initial correlation analyses were
performed using nonparametric Spearman’s correlations.
For subsequent analyses, the data were log-transformed
and analysis of covariance was used (with age as the covar-
iate) to analyze the differences between the groups. The
assumption of homogeneity of regression was tested
(P . .05). Partial correlation analyses were also conducted
to analyze the associations between the different variables.3. Results
In the present study, we investigated the potential of
agrin as a CSF biomarker for the early diagnosis of AD
using a specific ELISA immunoassay. The demographic
data for the 60 patients are presented in Table 1. The
P = .007 P = .88
P = .04 P = .009
Fig. 1. Agrin cerebrospinal fluid (CSF) concentration correlates with patient age only in patients with Alzheimer’s disease (AD). (A) Proteomic analysis of CSF
samples from those with subjective memory complaints (SMCs) (n5 4), stable mild cognitive impairment (MCI-S) (n5 4), MCI converting to AD (MCI-AD)
(n 5 5), and AD (n 5 5). The spectral counts of agrin peptides in CSF increased with disease progression. (B) Correlation analysis showed a significant as-
sociation between agrin and patient age. When the results were divided according to the different clinical groups, the CSF agrin concentration did not correlate
with age in the SMC cases (n5 13) (C) but it did in thosewith mild (n5 18) (D) and severe (n5 18) (E) AD. Correlation coefficients and P values are presented
in the inserts. Regression line is shown, and dot lines represent the 95% confidence intervals. *P  .05.
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concentrations of Ab42, t-Tau, and p-Tau, but not in age
or sex, a reflection of the selection criteria. Correlation
analysis revealed a significant interaction between the
agrin CSF concentration and patient age (Fig. 1B). The
correlation analyses run within each diagnostic group re-
vealed that the interaction between patient age and agrin
levels was specific to, and strengthened in, the patients
with dementia compared with controls (Fig. 1C–E).
Consequently, patient age was introduced as a covariate
in subsequent statistical models.
Our data revealed no significant differences in agrin CSF
concentration between the different clinical groups (Fig. 2A).
No significant associations were found between the agrin
CSF concentration and MMSE scores or the CSF concentra-
tion of t-Tau, p-Tau, and Ab42, although a positive tendency
was observed in the latter (Fig. 2B–E). In summary, the data
indicate that the agrin CSF concentration cannot be used as a
biomarker for the early diagnosis of AD. However, our find-
ings did reveal an interesting association between the agrin
level and patient age in the patients with dementia and a ten-
dency for a correlation between agrin and Ab42.4. Discussion
In a previous hypothesis-free pilot proteomics study, we
found that the levels of agrin were significantly increased
in the AD CSF compared with the control CSF (Fig. 1A,n 5 5 per group). The discrepancy between our results and
the proteomics data is likely explained by the epitope recog-
nized by the antibody used in the current ELISA system.
This antibody detects a sequence within the N-terminal
110-kDa fragment, and the vast majority of the peptides
found in the proteomics study reside in the C-terminal re-
gion. In addition, the peptides sequences detected in this
ELISA lie within the laminin epidermal growth factor-like
and Kazal-like domains of the agrin protein, which can
form disulfide bonds [27,28]. Those properties might
prevent the detection of relevant peptides in the CSF and
consequently weaken the possibility of finding differences
between the clinical groups. Similarly, the present results
challenged those from another study that found increased
levels of soluble agrin in the postmortem hippocampus of
patients with AD in early stages of the disease [14]. The
discrepancy could again be attributable to the antibodies
used in our ELISA system, because the previous investiga-
tion used an in-house ELISA kit that detected the 50-
kDa C-terminal fragment of agrin. Taken together, we can
conclude that the N-terminal 110-kDa fragment of agrin is
not changed in ADCSF; however, whether the concentration
of the 50-kDa C-terminal fragment is modified between the
different patient groups requires additional investigation.
We observed a tendency for a positive correlation be-
tween the CSF levels of agrin and Ab42, suggesting an
association of agrin with AD pathologic features and,
more specifically, with Ab plaque formation. This agrees
Table 1
Demographic data of CSF sample
Variable
Proteomics analysis ELISA
SMC MCI-S MCI-AD AD SMC AD-M AD-S
Mean age (y) 60.3 6 4.5 62.1 6 3.2 66.2 6 6.4 63.9 6 6.6 60.2 6 2.61 60.9 6 3.00 60.4 6 3.21
Sex 4 4 5 5 20 20 20
Male 2 1 2 2 7 8 10
Female 2 3 3 3 13 12 10
Mean MMSE
Baseline 29.5 6 1.0 27.4 6 2.2 27.0 6 1.4 21.4 6 6.3 27 6 1.78 21.1 6 1.0* 15.3 6 1.9*,y
Follow-up — 28.4 6 2.0 25.0 6 2.5 20.8 6 5.6 NA NA NA
Ab42 (pg/mL) 838 6 133 875 6 201 499 6 78 384 6 146*
,y 888 6 211.5 491.5 6 185* 390.5 6 149.5*,y
t-Tau (pg/mL) 200 6 76 421 6 347 1071 6 248* 526 6 120 228 6 161 729 6 599* 679.5 6 856.25*
p-Tau (pg/mL) 47 6 16 73 6 48 138 6 37* 102 6 40 48 6 18.5 98.5 6 48.5* 95.5 6 81.25*
Abbreviations: Ab, amyloid-b; AD, Alzheimer’s disease; ELISA, enzyme-linked immunosorbent assay; MMSE, Mini Mental State Examination; MCI-S,
stable mild cognitive impairment; MCI-AD, MCI converting to AD; NA, not applicable; SMC, subjective memory complaints; AD-M, mild AD; AD-S, severe
AD; t-Tau, total Tau; p-Tau, phosphorylated Tau.
NOTE. Data reported as median and interquartile range or mean 6 standard deviation.
*At least P , .05 from SMC.
yAt least P , .05 from MCI-S or AD-M.
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with senile plaques in human AD brain tissue
[16,18,19]. Moreover, agrin was able to bind Ab,
accelerating the fibrillation process [19] and, thus, sug-
gesting a role in plaque formation. Taken together, previ-
ous data have indicated that agrin expression is changed
in AD tissue and could play an important role in the
development of this disorder [10,15]. However, according
to the present results, those changes are not clearly
reflected in CSF.P = .058
P = .769
Fig. 2. The agrin cerebrospinal fluid (CSF) concentration was not changed in tho
markers. (A) Agrin concentration in CSF from those with subjective memory comp
(n5 18). No significant difference was observed among the groups. Partial correl
(B), total Tau (t-Tau) (C), phosphorylated tau (p-Tau) (D), and Mini Mental State
presented in the inserts. Regression line is shown, and dot lines represent the 95%Although we did not observe a difference in the CSF
levels of N-terminal agrin between those with and without
AD, the strong correlation with patient age only in those
with dementia was striking. These results suggest that age
might produce greater and more detectable changes in the
levels of agrin CSF between those with and without AD,
which might be prompted by the greater heterogeneity of
AD pathologic features in older patients. The influence of
age on the agrin CSF concentration can be a relevant
concern, because the incidence of AD increases in olderP = .713
P = .992
se with Alzheimer’s disease (AD) and did not correlate with the classic AD
laints (SMCs) (n5 13), mild AD (AD-M) (n5 18), and severe AD (AD-S)
ation analysis results of CSF concentrations of agrin with amyloid-b (Ab42)
Examination (MMSE) scores (E). Correlation coefficients and P value are
confident intervals. ns, nonsignificant.
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aged 75 to 84 years and 44% in patients older than 84 years
[29]. Thus, it would be interesting to investigate agrin’s po-
tential as a CSF biomarker in older groups. Whether the cor-
relation between patient age and agrin CSF concentration
reflects an underlying pathologic process of aging and de-
mentia remains to be investigated.
In conclusion, the results of the present study showed no
difference in the concentration of agrin in CSF between con-
trols and patients with AD, indicating that agrin cannot be
used as an early biomarker for AD diagnosis using the current
assay.However, it remains to be investigatedwhether changes
in the agrin CSF concentrations would be detectable with a
different ELISA. In addition, the positive correlation of agrin
and patient age in patients with dementia suggests that
changes in the CSF agrin concentration might be visible in
older patients with more heterogeneous pathologic features.
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1. Systematic review: We used a hypothesis-free pro-
teomics approach to identify potential CSF AD bio-
markers. One of the candidates identified was agrin,
which might reflect plaque formation or synaptic
dysfunction, because it is involved in Ab fibrillation
and synaptogenesis. Increased levels of agrin were
previously found in early stages of AD.
2. Interpretation: Although agrin has been extensively
analyzed in AD postmortem tissue, its role in CSF
has never been investigated. Our results have re-
vealed that the changes found in human tissue cannot
be detected in CSF using the current immunoassay.
However, the results revealed that agrin correlates
with patient age only in the those with dementia.
3. Future directions: The levels of agrin in CSF should
be measured using a different immunoassay recog-
nizing a different agrin epitope. The association of
agrin and patient age indicates that the future analysis
should also include older cohorts in whom the inci-
dence of AD is greater. Those analyses will further
clarify whether the agrin level is changed in AD CSF.References
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